Spit test could predict lung damage in cystic fibrosis
NCT ID NCT02976714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find DNA markers (epigenetic biomarkers) in sputum that can predict how severe lung disease will become in people with cystic fibrosis. Researchers will collect sputum samples from 50 participants aged 12 to 30 over 18 months and analyze changes in DNA methylation. The goal is to develop a non-invasive way to forecast lung disease progression, not to treat or cure the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uhmontpellier
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a peer coach help young people take control of their chronic illness?
- Could a single antibiotic be enough for cystic fibrosis lung infections?
- Early use of powerful CF drugs may boost growth in young children
- Hands-On therapy may soothe cystic fibrosis pain without drugs
- Newborn screening study aims to catch rare diseases at birth
- Breath sniffing may reveal early clues to cystic fibrosis drug success